CROI 2026: Continued reports
13 March 2026. Related: Early access, Conference reports, CROI 33 (Retrovirus) 2026.
Simon Collins, HIV i-Base
The following reports are now published from the recent CROI 2026 conference held in Denver from 22 to 25 February,
Further reports will be added weekly to the list below.
A review of studies at CROI 2026 of weight loss drugs in people with HIV included short-term efficacy, reduced smoking cigarettes and intriguing results at repairing HIV-related gut damage.
This is the second randomised clinical study to report no benefit against gonorrhoea for gay men given the 4CMenB vaccine.
Phase 3 study chowing pritelivir is active against drug-resistant herpes.
A new once-daily small pill can effectively simplify ART for many on complicated combinations
This is the second randomised clinical study to report no benefit against gonorrhoea for gay men given the 4CMenB vaccine.
Phase 3 study chowing pritelivir is active against drug-resistant herpes.
Long-term results from this 8-year French PrEP study predominantly in gay men continues to show flexibility of 2:1:1 dosing and daily dosing.
The dose selection for this very exciting option for once-monthly oral PrEP.
An interesting study looking at future PrEP against HIV with drug resistance,
A statement by the conference organiser’s reflects the concerns of researchers to the current anti-science policies of the Trump administration.
An early overview covering new HIV drugs, new PrEP drugs, bNAbs, HIV complications, GLP-1 weight-busting drugs in people with HIV, cure-related research, key populations, impact of US policy changes, new monitoring testa and more.